Application and investment of AI in the pharmaceutical industry is rapidly gaining momentum. We bring together CEOs, CIOs, CTOs and Global AI, IT and Informatics Experts from leading pharmaceutical and technology companies to give strategic talks from a business perspective together with use cases from across the drug development pipeline.

Thursday, October 24

Harborview 3

7:45 am Registration Opens

8:00 Continental Breakfast (Harborview Foyer)

9:00 - 12:25 pm Plenary Keynote Sessions (Harborview)

12:25 pm Networking, Coffee & Dessert in the Expo (Commonwealth Hall)

Business Value Outcomes
Harborview 3

1:30 Opening Remarks 

Alan Louie, PhD, Research Director, Life Sciences, IDC

1:35 CO-PRESENTATION: Practical Application of AI in Pharma

Ryan Welsh, CEO, Kyndi

Faye O’Brien, Director, Performance, Metrics and Analytics, AstraZeneca

A discussion of how to really use information captured in CAPAs to inform decisions, better allocate resource and drive business value.

2:05 KEYNOTE: What Does the World's First Biotech Born in AI Do Differently and Why? 

Milind Kamkolkar, Chief Data Officer, Cellarity; Former Chief Data Officer, Sanofi 

A no-filtered perspective shared by someone who has been on many sides of the AI in Life Sciences spectrum from big pharma through start-up, and why the world needs the next format of biotech born in AI.

2:30 How to Integrate AI into the Pharmaceutical Business Model

Dorothee B. Bartels, PhD, Digital Real-World Data Expert; Former Chief Digital Science Officer, BI X (Boehringer Ingelheim’s Digital Lab)

There is great hope, and also great hype, on AI in changing the pharmaceutical business model. AI is yet another tool to support the change from blockbuster business to personalized medicine; however, only if appropriate and high-quality data are available and accessible can the vision become reality. Along the entire value chain, examples will be given how AI can and cannot support bringing innovative drugs to patients faster.

2:55 Linking Artificial Intelligence to Business Outcomes

Angeli Möller, PhD, Head of IT Business Partnering Research, Pharmaceuticals Division, Bayer

Innovative technologies like Artificial Intelligence can help us get the right treatment to the right patient at the right time. Investing in those technologies can lead to differentiating business capabilities and therefore, a competitive advantage. At Bayer Pharmaceuticals, we invest in lighthouse initiatives that use Artificial Intelligence to drive top-line and bottom-line growth, whilst simultaneously accelerating the digital transformation of our value chain.

3:20 Networking Break in the Expo (Commonwealth Hall)

4:05 Bridging Business and Technical Functions: How to Translate AI Between the Two

Eduardo Cornejo, ITS Digital Innovation Market Lead, Sanofi

Ever been in a room where business and IT don’t seem to be speaking the same language? It often seems that our colleagues develop their own understanding and their own language around technology, which makes it more difficult to work on projects. This is especially true for projects revolving around Artificial Intelligence. At Sanofi, we developed a short program that brings everyone to the same page and language of AI, so that we can run our projects more effectively.

4:30 PANEL: Assessing the Impact of AI on Business Strategies in the Pharmaceutical Industry

Moderator: Annastasiah Mudiwa Mhaka, PhD, Co-Founder & President, Alliance for Artificial Intelligence in Healthcare

Panelists: Brian Kesselman, Head, IT & Digital Transformation, Pharma, Bayer

Dorothee B. Bartels, PhD, Digital Real-World Data Expert; Former Chief Digital Science Officer, BI X (Boehringer Ingelheim’s Digital Lab)

Sebastien Lefebvre, Senior Director, Data Sciences, Genomics and Bioinformatics, Alexion Pharmaceuticals

5:05 Networking Reception in the Expo (Commonwealth Hall)

6:30 Meetup Groups (Cityview)

7:30 Close of Day 2

FRIDAY, OCTOBER 25

Harborview 2

7:45 am Registration Opens

8:00 Continental Breakfast (Harborview Foyer)

8:15 am - 12:30 pm Plenary Keynote Sessions (Harborview)

12:30 Networking, Coffee & Dessert in the Expo - Last Chance for Viewing (Commonwealth Hall)

Cross Functional Impact of AI
Harborview 2

1:45 Opening Remarks

Mike Townsend, Research Manager, Life Sciences Commercial Strategies, IDC

1:50 Medication Safety – AI

Ram Subramanian, CTO, Engineering, PerceptiMed, Inc.

This talk will discuss the current issues that exist with regard to medication safety at multiple levels in various areas of health care from production, pharmacy dispensing to administration at hospitals & managed care facilities and even at home. The talk will also include how AI is playing a role in managing these issues.

2:20 KEYNOTE: An Integrated Approach of AI in the Pharma Industry

John Baldoni, PhD, Chief Technical Officer, Integral Health

This talk will assess the cross functional impact of AI from the diagnosis of the disease, discovery of a molecule, conducting the clinical trials and the therapeutic and commercial outcomes.

2:45 The Nature of an AI Revolution and What it Means for Pharma

Peter Henstock, PhD, AI & Machine Learning Lead, Pfizer

AI launched in the media about 2.5 years ago describing revolutionary transforms of industries, promises, hype, and predictions of the next AI Winter. Attention cycles within the media last about 3 years. Within pharma, we are only just starting to leverage AI and it certainly doesn’t feel like a revolution. Are we at the beginning or the end? This talk examines past technology revolutions to suggest what we are to do now.

3:10 Networking Break (Plaza & Harbor Level Atriums)

3:25 Transforming Portfolio Decision Making Through the Use of AI

Grace You, PhD, Director, Head of Global Portfolio Management, Valuation & Analytics, EMD Serono

Using machine learning models in the context of risk management and probability of success calculation, as well as eNPV and scenario building: A practical application.

DISRUPTING Pharmacovigilance and Drug Discovery
Harborview 2

3:45 Leveraging AI to Transform Pharmacovigilance

Srikanth Ramakrishnan, Business Technology Leader, Information Technology, Johnson & Johnson

Reimagining pharmacovigilance for this new world. From being reactive, periodic, and compliance-focused to integrated and real-time surveillance.

4:05 PANEL: Revolutionizing Drug Discovery with Artificial Intelligence and Machine Learning

• Accelerating drug discovery through the power of microscopy images
• Using AI to digitally transform the drug discovery industry
• Disrupting drug discovery: Precision medicine, biomarkers, target identification and screening
• What are successful pharma companies doing today to prepare for a data-fuelled, machine learning future?

Moderator: Alex Zhavoronkov, PhD, Founder, Insilico, Medicine

Jeffrey Lu, CEO, Engine Biosciences

Anne Carpenter, PhD, Institute Scientist, Imaging Platform Senior Director, Broad Institute of Harvard and MIT

Imran Haque, PhD, VP Data Science, Recursion Pharmaceuticals

4:45 Close of AI World 2019